Radiofrequency (RF) Ablation Prospective Outcomes Study
Launched by BOSTON SCIENTIFIC CORPORATION · Dec 12, 2020
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain per local Directions for Use (DFU)
- • Signed a valid, IRB/EC/REB-approved informed consent form
- Key Exclusion Criteria:
- • Meets any contraindications per locally applicable Directions for Use (DFU)
- • Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments
About Boston Scientific Corporation
Boston Scientific Corporation is a global leader in medical device innovation, dedicated to providing solutions that enhance patient care and improve clinical outcomes. With a strong focus on advancing the treatment of various medical conditions, Boston Scientific develops and manufactures a diverse range of products across multiple specialties, including cardiology, urology, and endoscopy. The company is committed to rigorous clinical research and development, ensuring that its devices meet the highest standards of safety and efficacy. Through collaboration with healthcare professionals and ongoing investment in technology and education, Boston Scientific strives to deliver breakthrough therapies that address unmet medical needs and empower patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
Toledo, Ohio, United States
Geldrop, , Netherlands
Quincy, Illinois, United States
Tucson, Arizona, United States
London, , United Kingdom
Düsseldorf, , Germany
Sewickley, Pennsylvania, United States
Edina, Minnesota, United States
Huntersville, North Carolina, United States
Loveland, Ohio, United States
Mesa, Arizona, United States
Westport, Connecticut, United States
Cincinnati, Ohio, United States
Gainesville, Florida, United States
Brugge, , Belgium
Olbia, , Italy
Antwerp, , Belgium
Patients applied
Trial Officials
Natalie Bloom Lyons, M.S.
Study Director
Boston Scientific Corporation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials